Skip to content
★ Sign in to follow
基創

基米-創 Stock: price and insider trades · Taiwan

TW·Mcap NT$1.2BHealth Care

基米-創: what insiders have been doing

基米-創 has a thin disclosure history in our data (latest filing: 14 May 2021). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by TWSE / TPEx (MOPS). They describe what insiders did and are not a recommendation.

Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 23,717 of 26,911 companies
23.7
score / 100
Value
18
Quality
29
FCF yld-14%
Earn yld-3.3%
EV/EBITDA·
ROE-8.3%
Gross mgn33%
Net mgn-5.6%
Debt/EBITDA·
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

NT$15
Analyst consensus
·
Income statement
RevenueNT$708.4M
Gross profitNT$231.4M33% margin
EBITDANT$23M3% margin
Net income-NT$39.4M-3.6% margin
Valuation
PER (forward)-251.7x
P/Book1.8x
Beta-0.15
Balance sheet & cash
Market capNT$1.2B
Total debtNT$628.2M
Free Cash Flow-NT$171.6M
Debt / Equity72%
Profitability & ownership
ROE-8.3%
ROA-5.8%
% institutions0.0%
Last declaration on 14 May 2021
Declarations5 total
  • ●
    ManagerExecutives
    €288kest.0MOPS
    585,000 sharesShareTWSETWMOPS:4195:110/05/14:趙盈婷:1hjfr47
  • ●
    SupervisorExecutives
    €79kest.0MOPS
    150,000 sharesShareTWSETWMOPS:4195:105/09/21:黃苙源:1suw6cj
  • ●
    SupervisorExecutives
    €83kest.0MOPS
    150,000 sharesShareTWSETWMOPS:4195:105/08/18:黃苙源:0ntl6nc
  • ●
    SupervisorExecutives
    €79kest.0MOPS
    150,000 sharesShareTWSETWMOPS:4195:105/07/15:黃苙源:100wtc4
  • ●
    SupervisorExecutives
    €81kest.0MOPS
    150,000 sharesShareTWSETWMOPS:4195:105/06/14:黃苙源:1n1976q

5 of 5 declarations

About 基米-創

基米-創 is a company listed on the XTAI market, specializing in the development of innovative solutions. It focuses on creating technological products to enhance business efficiency.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations